Zoom

Tirzepatide Pre-filled Pen 10mg Weight Loss

Double action, réglage au clic.

Tirzepatide without a single step of preparation. A dual GIP and GLP-1 agonist, delivered as a ready-to-use pen: the solution is already in the cartridge, the dose is set on a dial. No reconstitution, no bacteriostatic water, no syringe to hunt down at a pharmacy. 10 mg in 3 ml, which is four weeks at the documented starting step. Four needles are included: you inject the day it arrives, no pharmacy run. For research use.

99,00 €

Tax included • Free delivery from 99€

Unavailable

Tirzepatide is a dual GIP and GLP-1 receptor agonist, the most studied molecule of its generation after semaglutide. In a pre-filled pen it loses what puts people off research protocols: reconstitution, volume calculation and drawing up with a syringe. The solution is ready inside the cartridge and the dose is set on a dial.

Science

01
Mechanism of action

Tirzepatide activates two incretin receptors at once, GIP and GLP-1. This dual action sets it apart from GLP-1-only agonists and accounts for the scale of the metabolic effects reported in the literature. Retatrutide adds a third axis, the glucagon receptor. All three belong to the same family and follow the same step-up logic.

Clinical data

02Clinical studies

The tirzepatide clinical program spans two arms: type 2 diabetes (SURPASS) and obesity without diabetes (SURMOUNT). Phase III trial density is substantial and positions the molecule as one of the best-documented incretin agents to date.

SURPASS-1 (Rosenstock 2021, Lancet) compared tirzepatide 5/10/15mg weekly to placebo in 478 drug-naive T2D patients over 40 weeks. HbA1c reductions: -1.87% (5mg), -1.89% (10mg), -2.07% (15mg) vs -0.04% placebo. Weight loss: -7.0 to -9.5 kg dose-dependent. SURPASS-2 (Frias 2021, NEJM) was the pivotal head-to-head trial against semaglutide 1mg in 1879 patients over 40 weeks. Tirzepatide 15mg produced HbA1c reduction -2.30% vs -1.86% for semaglutide 1mg, and weight loss -11.2 kg vs -5.7 kg. This trial established the metabolic superiority of the dual agonist over the reference GLP-1 mono-agonist.

SURPASS-3 (Ludvik 2021) added tirzepatide to metformin vs insulin degludec in 1437 patients over 52 weeks: marked superiority in HbA1c reduction and weight loss, with fewer hypoglycemia events. SURPASS-4 (Del Prato 2021, Lancet) extended evaluation to high cardiovascular risk patients over 104 weeks: durable HbA1c and weight reductions, reassuring cardiovascular profile. SURPASS-5 (Dahl 2022, JAMA) tested addition to insulin glargine: HbA1c -2.40% (15mg), weight -10.9 kg, substantial metabolic improvement.

The SURMOUNT program targets obesity without diabetes. SURMOUNT-1 (Jastreboff 2022, NEJM) enrolled 2539 adults BMI >= 30 (or >= 27 with comorbidities) over 72 weeks. Mean weight loss: -15.0% (5mg), -19.5% (10mg), -20.9% (15mg) vs -3.1% placebo. 50.1% of 15mg patients reached >= 20% weight loss, 36.2% reached >= 25%. These figures position tirzepatide at an unprecedented level for pharmacological obesity treatment, approaching reductions observed in sleeve gastrectomy bariatric surgery.

SURMOUNT-2 (Garvey 2023, Lancet) validated the effect in diabetic obese patients (-13.4% @15mg over 72 weeks). SURMOUNT-3 (Wadden 2023, Nat Med) showed that after a 12-week intensive diet lead-in, adding tirzepatide 10/15mg generated -18.4% additional loss over 72 weeks vs +2.5% placebo. SURMOUNT-4 (Aronne 2024, JAMA) tested withdrawal: after 36 weeks of maximal tirzepatide followed by 52 weeks of maintenance or discontinuation, the discontinuation group regained 14.0% of body weight while the maintenance group lost an additional 5.5%. Practical conclusion: ongoing therapy is required to preserve benefit, consistent with obesity as a chronic disease.

Ancillary data support systemic benefits. SURPASS-CVOT (ongoing cardiovascular trial, results expected 2025-2026) will compare tirzepatide to dulaglutide in 13299 high-CV-risk T2D patients. SYNERGY-NASH (Loomba 2024, NEJM) documented MASH resolution without fibrosis worsening in 51.8% of tirzepatide 10mg patients vs 9.8% placebo. Effects on sleep apnea (SURMOUNT-OSA, Malhotra 2024 NEJM) show a 55% reduction in apnea-hypopnea index at 52 weeks. These data sketch a cross-cutting therapeutic profile few agents share.

In research these references structure protocol design: titration regimens used in trials (2.5mg weeks 1-4 then +2.5mg every 4 weeks to target dose) serve as a methodological framework for exploratory cohorts, and stopping criteria (severe gastrointestinal events, pancreatitis, hypersensitivity reactions) inform exclusion criteria for observational work.

1
ObésitéTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (SURMOUNT-1 Investigators) · New England Journal of Medicine · 2022
2
ComparaisonTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías JP, Davies MJ, Rosenstock J, et al. (SURPASS-2 Investigators) · New England Journal of Medicine · 2021
3
Double agonisteEfficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)
Rosenstock J, Wysham C, Frías JP, et al. · The Lancet · 2021

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

Documented protocols start at 2.5 mg per week and step up, holding each level for several weeks before increasing: 2.5, then 5, 7.5, 10 mg. One weekly subcutaneous injection, same day each week. This pen holds 10 mg in 3 ml, so it covers four weeks at the starting step and two at 5 mg. It is the format that matches an entry cycle exactly. The dose reads off the dial, there are no syringe marks to count.

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

What is normal on arrivalThe observations that worry customers, and are not defects

The pen carries a handwritten marking: the product initials and the dose. This is our dose marker on the pen body. Check that it matches your order.
The needles are in the box, not on the pen. Four screw-on needles, a new one for each injection.
The liquid is clear and colourless, sometimes with a small air bubble. That is expected. Priming, before the first injection, clears the bubble.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: cloudy or coloured liquid, visible particles, a cracked pen or a dial that will not turn. In those exact cases, write to us with a photo and we will take the pen back.

Handling

04Storage & handling

Between 2 and 8 degrees, refrigerated, away from light, and never frozen. Unlike a lyophilised powder, a pre-filled pen already holds a solution: the cold chain matters from delivery onwards. A few days in transit at ambient temperature is accounted for by this type of formulation, but the pen goes into the fridge as soon as the parcel is opened. Do not fit the needle before injecting, and change it every time.

01Do I need to add bacteriostatic water?

No, and that is the whole point of this format. The solution is already prepared inside the cartridge. Bacteriostatic water is only needed for vials of lyophilised powder.

02How many weeks does one pen last?

Four weeks at the 2.5 mg starting step, two weeks at 5 mg. That is a full entry cycle in a single pen.

03Are needles included?

Four needles are included, enough for a starting cycle. Beyond that, refills are ordered separately in packs of ten.

04How is this different from the Tirzepatide vial?

The molecule is identical. The pen removes reconstitution, volume maths and buying a syringe; the vial leaves you in control of the concentration.

05Can it be kept out of the fridge?

A few days in transit at ambient temperature is accounted for, but the pen must go into the fridge on arrival and stay there between injections.

06Tirzepatide or Retatrutide?

Two distinct molecules. Tirzepatide acts on two receptors, Retatrutide on three. They are not interchangeable and are not dosed at the same values.

07How do I set the dose?

On the dial, as on a pharmacy pen. No syringe marks to count, no volume to convert.

Comparatif

Pen or vial?

Against the 10 mg Tirzepatide vial, the pen removes three steps and two purchases: no bacteriostatic water, no syringe, no concentration maths. The vial remains the choice for anyone who wants to set their own concentration or split it differently. Against Retatrutide in pen form, Tirzepatide acts on two receptors instead of three and is dosed in higher milligram steps: they are two distinct molecules, not two strengths of the same product.

Full guide: Tirzepatide — mechanism, studies, dose comparison

Metabolism

Product information

Our other ready-to-use pens